The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Amyloid beta 42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerization
Abstract
Following ectodomain shedding by β-secretase, successive proteolytic cleavages within the transmembrane sequence (TMS) of the amyloid precursor protein (APP) catalyzed by γ-secretase result in the release of amyloid-β (Aβ) peptides of variable length. Aβ peptides with 42 amino acids appear to be the key pathogenic species in Alzheimer’s disease, as they are believed to initiate neuronal degeneration. Sulindac sulfide, which is known as a potent γ-secretase modulator (GSM), selectively reduces Aβ42 production in favor of shorter Aβ species, such as Aβ38. By studying APP–TMS dimerization we previously showed that an attenuated interaction similarly decreased Aβ42 levels and concomitantly increased Aβ38 levels. However, the precise molecular mechanism by which GSMs modulate Aβ production is still unclear. In this study, using a reporter gene-based dimerization assay, we found that APP–TMS dimers are destabilized by sulindac sulfide and related Aβ42-lowering compounds in a concentration-dependent manner. By surface plasmon resonance analysis and NMR spectroscopy, we show that sulindac sulfide and novel sulindac-derived compounds directly bind to the Aβ sequence. Strikingly, the attenuated APP–TMS interaction by GSMs correlated strongly with Aβ42-lowering activity and binding strength to the Aβ sequence. Molecular docking analyses suggest that certain GSMs bind to the GxxxG dimerization motif in the APP–TMS. We conclude that these GSMs decrease Aβ42 levels by modulating APP–TMS interactions. This effect specifically emphasizes the importance of the dimeric APP–TMS as a promising drug target in Alzheimer’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“APP dimerization has been proposed to enhance Aβ production,54–56”
From Evidence for a clathrin-independent endocytic pathway for APP internalization in the neuronal somatodendritic compartment (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 9×
“5 μM sulindac sulfide can be directly compared to GxxxG mutants G29A and G33A (5, 7).”
BackgroundMethodResultInfluentialSelf-citationSoluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
The secretases: enzymes with therapeutic potential in Alzheimer disease
De Strooper, B., Vassar, R., & Golde, T. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.218 · Cited by 799
Research works printed but not linked: 30
- 10.1523/JNEUROSCI.2362-09.2009 · DOI · Paper page
- 10.1074/jbc.M109.088005 · DOI · Paper page
- 10.1038/sj.emboj.7601616 · DOI · Paper page
- 10.1007/s00018-008-7462-2 · DOI · Paper page
- 10.1038/nm1235 · DOI · Paper page
- 10.1074/jbc.M303592200 · DOI · Paper page
- 10.1038/nm1112 · DOI · Paper page
- 10.1021/jm00142a016 · doi:10.1021/jm00142a016
- 10.1021/jm00142a015 · doi:10.1021/jm00142a015
- 10.1016/j.neuropharm.2008.02.009 · DOI
- 10.1038/nature07055 · DOI · Paper page
- 10.1021/bi901839d · DOI
- 10.1006/jmbi.1996.0595 · DOI · Paper page
- 10.1016/j.bbrc.2003.10.203 · DOI
- 10.1159/000095270 · DOI
- 10.1002/anie.200352587 · DOI
- 10.1074/jbc.M700618200 · DOI
- 10.1074/jbc.M708046200 · DOI
- 10.1016/j.molcel.2004.06.037 · DOI
- 10.1242/jcs.112.23.4415 · DOI
- 10.1074/jbc.M108681200 · DOI · Paper page
- 10.1074/jbc.M409430200 · DOI
- 10.1074/jbc.M513250200 · DOI
- 10.1021/bi901237k · DOI
- 10.1002/anie.200353089 · DOI
- 10.1021/jm960116z · DOI
- 10.1523/JNEUROSCI.1336-09.2009 · DOI
- 10.1074/jbc.M303547200 · DOI
- M Vaara, The outer membrane permeability-increasing action of linear analogues of polymyxin B nonapeptide. Drugs Exp Clin Res 17, 437–443 (1991).
- 10.1097/00001756-199805110-00043 · DOI
Cited by
Physiological Functions of APP Family Proteins
Muller, U. C., & Zheng, H. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006288 · Cited by 310
γ-Secretase inhibitors and modulators
Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 272
Learning by Failing: Ideas and Concepts to Tackle γ-Secretases in Alzheimer's Disease and Beyond
De Strooper, B., & Chávez Gutiérrez, L. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124309 · Cited by 119
Hahn, S., Brüning, T., Ness, J., Czirr, E., Baches, S., Gijsen, H., Korth, C., Pietrzik, C. U., Bulic, B., & Weggen, S. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07118.x · Cited by 42
Self-citationLi, X., Uemura, K., Hashimoto, T., Nasser-Ghodsi, N., Arimon, M., Lill, C. M., Palazzolo, I., Krainc, D., Hyman, B. T., & Berezovska, O. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.002 · Cited by 38
“Soluble Aβ, and to a lesser extent Aβ fibrils, have been shown to bind to APP (Lorenzo et al., 2000; Richter et al., 2010).”
Metadata
- Authors
- Richter, L., Munter, L.-M., Ness, J., Hildebrand, P. W., Dasari, M., Unterreitmeier, S., Bulic, B., Beyermann, M., Gust, R., Reif, B., Weggen, S., Langosch, D., & Multhaup, G.
- Affiliations
- Institut für Chemie und Biochemie, Freie Universität Berlin, 14195 Berlin, Germany;
- Institut für Neuropathologie, Heinrich-Heine-Universität, 40225 Düsseldorf, Germany;
- Institut für Medizinische Physik und Biophysik, Charité, 10117 Berlin, Germany;
- Leibniz-Institut für Molekulare Pharmakologie, 13125 Berlin, Germany;
- Lehrstuhl für Chemie der Biopolymere, Technische Universität München, 85354 Freising, Germany;
- Center for Advanced European Studies and Research, 53175 Bonn, Germany; and
- Institut für Pharmazie, Freie Universität Berlin, 14195 Berlin, Germany
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2010-08-02
- Volume
- 107
- Issue
- 33
- Pages
- 14597-14602
- ISSN
- 0027-8424
- 1091-6490
- Cited by
- 99
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amyloid beta 42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerization. https://app.cochat.ai/papers/10.1073/pnas.1003026107
- The paper
- Richter, L., Munter, L.-M., Ness, J., Hildebrand, P. W., Dasari, M., Unterreitmeier, S., Bulic, B., Beyermann, M., Gust, R., Reif, B., Weggen, S., Langosch, D., & Multhaup, G. (2010). Amyloid beta 42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1003026107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.